Clinical Evaluation of Nicergoline in Cerebrovascular Dementia Disorders: Therapeutic Effects of Nicergoline Powder.:Therapeutic Effects of Nicergoline Powder

概要

論文の詳細を見る
A powder preparation of the nicergoline "Sermion®" (TA-079 powder, containing 5mg of nicergoline in a 0.5g pouch) was administered to 29 patients with mild to moderate dementia due to cerebrovascular disease (15mg/day for eight weeks), and its efficacy, safety, and utility were evaluated.Marked improvement was noted in delirium, headache, heavy-headedness, anxiety, irritation, bad temper, and problem behavior.The final overall improvement ratings were as follows: improved or better, 37.9%; slightly improved or better, 69%; unchanged, 27.6%; and aggravated, 3.4% (1 case).This drug for cerebrovascular disease was slightly useful or better in 69%.Side effects were not found in all cases.
一般社団法人日本臨床薬理学会の論文